[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100518735":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":23,"centralContacts":27,"locations":35,"responsibleParty":147,"collaborators":150,"id":154,"slug":155,"hasResults":156,"nctId":157,"briefTitle":158,"officialTitle":158,"acronym":10,"eligibilityCriteria":159,"healthyVolunteers":160,"sex":161,"minAge":162,"maxAge":10,"enrollmentInfo":163,"targetDuration":10,"studyType":166,"phases":10,"briefSummary":167,"conditions":168,"keywords":10,"overallStatus":38,"whyStopped":10,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":176,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":183,"locationsCount":184},{"fullName":5,"class":6},"Columbia University","OTHER",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"ATTR Negative",null,"Participants who have undergone previous lumbar spinal, and\u002For carpel tunnel surgery will provide medical record data and spinal specimen for analysis of presence of ATTR amyloid.",{"label":13,"type":10,"description":14,"interventionNames":15},"ATTR Positive","Participants who have undergone previous lumbar spinal, and\u002For carpel tunnel surgery will provide medical record data, spinal specimen, prospective data from cardiac workup with confirmed ATTR amyloid in spinal specimen then undergo cardiac workup for cardiac phenotyping\u002Fgenotyping.",[16],"Diagnostic Test: Tc99-PYP or Tc99-HDMP Scan",[18],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":10},"DIAGNOSTIC_TEST","Tc99-PYP or Tc99-HDMP Scan","Difference in ATTR-CA prevalence between subjects with TTR and indeterminate amyloid deposits in their spine by myocardial uptake of Tc99-PYP.",[13],[24],{"name":25,"affiliation":5,"role":26},"Mathew S Maurer, MD","PRINCIPAL_INVESTIGATOR",[28,32],{"name":25,"role":29,"phone":30,"phoneExt":10,"email":31},"CONTACT","212-932-4537","msm10@cumc.columbia.edu",{"name":33,"role":29,"phone":30,"phoneExt":10,"email":34},"Samantha L Guadalupe, MHA","slg2172@cumc.columbia.edu",[36,64,85,101,112,127],{"facility":37,"status":38,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"Cedars-Sinai Medical Center","RECRUITING","Beverly Hills","California","90211","United States","US",{"type":45,"coordinates":46},"Point",[47,48],-118.40036,34.07362,{"lat":48,"lon":47},[51,55,59,61],{"name":52,"role":29,"phone":53,"phoneExt":10,"email":54},"Shruti Shantharam","310-248-8365","shruti.shantharam@csmns.org",{"name":56,"role":29,"phone":57,"phoneExt":10,"email":58},"Christine Sumbi","310-248-8327","christine.sumbi@csmns.org",{"name":60,"role":26,"phone":10,"phoneExt":10,"email":10},"Jignesh Patel, MD",{"name":62,"role":63,"phone":10,"phoneExt":10,"email":10},"Michelle Kittleson, MD,PhD","SUB_INVESTIGATOR",{"facility":65,"status":38,"city":66,"state":67,"zip":68,"country":42,"countryCode":43,"cosmosGeoPoint":69,"geoPoint":73,"contacts":74},"Tufts Medical Center","Boston","Massachusetts","02111",{"type":45,"coordinates":70},[71,72],-71.05977,42.35843,{"lat":72,"lon":71},[75,79,83,84],{"name":76,"role":29,"phone":77,"phoneExt":10,"email":78},"Ayan Patel, MD","617-636-4184","ayan.patel@tuftsmedicine.org",{"name":80,"role":29,"phone":81,"phoneExt":10,"email":82},"James Kryzanski, MD","617-636-8585","james.kryzanski@tuftsmedicine.org",{"name":76,"role":26,"phone":10,"phoneExt":10,"email":10},{"name":80,"role":63,"phone":10,"phoneExt":10,"email":10},{"facility":86,"status":38,"city":66,"state":67,"zip":87,"country":42,"countryCode":43,"cosmosGeoPoint":88,"geoPoint":90,"contacts":91},"Boston Medical Center","02359",{"type":45,"coordinates":89},[71,72],{"lat":72,"lon":71},[92,96,100],{"name":93,"role":29,"phone":94,"phoneExt":10,"email":95},"Frederick Ruberg, MD","617-638-8771","frederick.ruberg@bmc.org",{"name":97,"role":29,"phone":98,"phoneExt":10,"email":99},"Denise Fine","617-638-8716","denise.fine@bmc.org",{"name":93,"role":26,"phone":10,"phoneExt":10,"email":10},{"facility":102,"status":103,"city":104,"state":105,"zip":106,"country":42,"countryCode":43,"cosmosGeoPoint":107,"geoPoint":111,"contacts":10},"Mayo Clinic","ACTIVE_NOT_RECRUITING","Rochester","Minnesota","55905",{"type":45,"coordinates":108},[109,110],-92.4699,44.02163,{"lat":110,"lon":109},{"facility":113,"status":38,"city":114,"state":114,"zip":115,"country":42,"countryCode":43,"cosmosGeoPoint":116,"geoPoint":120,"contacts":121},"Columbia University Irving Medical Center","New York","10032",{"type":45,"coordinates":117},[118,119],-74.00597,40.71427,{"lat":119,"lon":118},[122,125,126],{"name":123,"role":29,"phone":30,"phoneExt":10,"email":124},"Jeffeny DeLosSantos, MHA","jd3456@cumc.columbia.edu",{"name":33,"role":29,"phone":30,"phoneExt":10,"email":34},{"name":25,"role":26,"phone":10,"phoneExt":10,"email":10},{"facility":128,"status":38,"city":129,"state":130,"zip":131,"country":42,"countryCode":43,"cosmosGeoPoint":132,"geoPoint":136,"contacts":137},"Cleveland Clinic","Cleveland","Ohio","44195",{"type":45,"coordinates":133},[134,135],-81.69541,41.4995,{"lat":135,"lon":134},[138,142,146],{"name":139,"role":29,"phone":140,"phoneExt":10,"email":141},"Mazen Hanna, MD","216-444-3490","hannam@ccf.org",{"name":143,"role":29,"phone":144,"phoneExt":10,"email":145},"Lauren Ives, RN","216-316-3370","ivesl@ccf.org",{"name":139,"role":26,"phone":10,"phoneExt":10,"email":10},{"type":26,"investigatorFullName":148,"investigatorTitle":149,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Mathew S. Maurer, MD","Arnold and Arlene Goldstein Professor of Cardiology (in Medicine, Dept of Medicine Cardiology)",[151],{"name":152,"class":153},"National Institute on Aging (NIA)","NIH","100518735","analysis-of-lumbar-spine-stenosis-specimens-for-identification-of-transthyretin-cardiac-amyloidosis-100518735",false,"NCT06034405","Analysis of Lumbar Spine Stenosis Specimens for Identification of Transthyretin Cardiac Amyloidosis","Inclusion Criteria:\n\n1. Clinically indicated spinal decompressive surgery within 20 years prior to enrollment.\n2. Age ≥50 years at the time of the surgery.\n3. Able to understand and sign the informed consent document after the nature of the study has been fully explained.\n\nExclusion Criteria:\n\nThe presence of any of the following excludes eligibility for enrollment in this study:\n\n1. Confirmed primary amyloidosis (AL) or secondary amyloidosis (AA).\n2. Known TTR amyloidosis.\n3. Other reason that would make the subject inappropriate for entry into this study.",true,"ALL","50 Years",{"count":164,"type":165},1663,"ESTIMATED","OBSERVATIONAL","Primary objective:\n\nTo identify older adults with transthyretin cardiac amyloidosis (ATTR-CA) early in the course of the illness, at a time when disease modifying therapies are most effective.\n\nThe specific aims of this epidemiologic investigation include:\n\n1. To identify subjects with previous lumbar spinal stenosis (LSS) Surgery who have evidence of transthyretin (TTR) amyloid deposits in spinal specimens and could be at risk for ATTR cardiac amyloidosis.\n2. To evaluate for ATTR-CA among those with localized TTR in the spinal tissue.\n\nThe study will also explore the following:\n\n1. The prevalence of amyloid in lumbar spinal stenosis specimens by Congo Red staining.\n2. The prevalence of TTR deposits among subjects with amyloid as determined by mass spectrometry.\n3. Evaluation of a novel artificial intelligence technique for that can identify amyloid histologically with standard H\\&E staining.\n4. Difference in ATTR-CA prevalence between subjects with TTR and indeterminate amyloid deposits in subject's spine by myocardial uptake of technetium pyrophosphate scan (Tc99-PYP).",[169,170,171,172,173,174],"Lumbar Spinal Stenosis","Cardiac Amyloidosis","ATTR Amyloidosis Wild Type","ATTR Gene Mutation","ATTRV122I Amyloidosis","Cardiomyopathy, Hypertrophic","2026-06-02",{"date":177,"type":178},"2026-06-04","ACTUAL",{"date":180,"type":178},"2023-09-19",{"date":182,"type":165},"2028-05",{"name":5,"class":6},6]